Active substanceCefoperazone + SulbactamCefoperazone + Sulbactam
Similar drugsTo uncover
  • Bakperazone
    powder w / m in / in 
  • Baktsefort
    powder w / m in / in 
    KRASFARMA, JSC     Russia
  • Sulzencef®
    powdersolution w / m in / in 
    SYNTHESIS, OJSC     Russia
  • Sulmover®
    powdersolution w / m in / in 
  • Sulmover®
    powdersolution w / m in / in 
  • Sulperazone
    powdersolution w / m in / in 
  • SULPERATEF®
    powdersolution w / m in / in 
    ABOLMED, LLC     Russia
  • Sulceph
    powdersolution w / m in / in 
    Medocemi Co., Ltd.     Cyprus
  • Cebanex
    powdersolution w / m in / in 
  • Cebanex
    powdersolution w / m in / in 
  • Cefbactam®
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • Cefoperazone and Sulbactam Jodas
    powdersolution w / m in / in 
    JODAS EKSPOIM, LLC     Russia
  • Cefoperazone and Sulbactam Spencer
    powdersolution w / m in / in 
    Spencer Pharma UK Limited     United Kingdom
  • Cefpar SV
    powdersolution w / m in / in 
  • Dosage form: & nbspPowder for the preparation of solution for intravenous and intramuscular injection.
    Composition:
    1 bottle contains:

    Active substances: sodium cefoperazone (equivalent to cefoperazone) and sodium sulbactam (equivalent to sulbactam) - 0.5 g + 0.5 g; 1.0 g + 1.0 g.
    Description:
    Powder from white to almost white.

    Pharmacotherapeutic group:Antibiotic-cephalosporin + beta-lactamase inhibitor.
    ATX: & nbsp

    J.01.D.D.62   Cefoperazone in combination with other drugs

    Pharmacodynamics:
    The antibacterial component of cefoperazone + sulbactam is cefoperazone Third-generation cephalosporin, which acts on sensitive microorganisms during their active propagation by inhibiting the biosynthesis of the mucopeptide of the cell wall. Sulbactam does not have clinically significant antibacterial activity (except for Neisseriaceae and Acinetobacter). However, it was noted that it is an irreversible inhibitor of most of the major beta-lactamases that are produced by microorganisms resistant to beta-lactam antibiotics. The ability of sulbactam to prevent the destruction of penicillins and cephalosporins by resistant microorganisms was confirmed in studies using resistant strains for which sulbactam possessed a pronounced synergy with penicillins and cephalosporins.In addition, sulbactam interacts with certain penicillin-binding proteins, so cefoperazone + sulbactam often has a more pronounced effect on sensitive strains than one cefoperazone.
    The combination of sulbactam and cefoperazone is active against all microorganisms sensitive to cefoperazone. In addition, it has a synergistic effect on various microorganisms, in particular: Haemophilus influenzae, Bacteroides spp., Staphylococcus spp., Acinetobacter calcoaceticus, Enterobacter aerobes, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Morganella morganii, Citrobacter freundii, Enterobacter cloacae, Citrobacter freundii diversus.
    Cefoperazone + sulbactam is active in vitro against a wide range of clinically relevant microorganisms.

    - Gram-positive microorganisms

    Staphylococcus aureus (producing and not producing penicillinase), Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes (beta-hemolytic group streptococcus A), Streptococcus agalactiae (beta-hemolytic streptococcus group B), most other strains of beta-hemolytic streptococci, many strains Enterococcus faecalis.

    - Gram-negative microorganisms

    Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Haemophilus influenzae, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Providencia rettgeri, Providencia spp., Serratia spp. (including Serratia marcescens), Salmonella spp. and Shigella spp :, Pseudomonas aeruginosa and some others Pseudomonas spp., Acinetobacter calcoaceticus, Neisseria gonorrhoeae, Neisseria meningitidis, Bordetella pertussis, Yersinia enterocolitica.

    - Anaerobic microorganisms

    Gram-negative rods (including Bacteroides fragilis, others Bacteroides spp. and Fusobacterium spp.).

    Gram-positive and Gram-negative cocci (Including Peptococcus spp., Peptostreptococcus spp. and Veillonella spp.).

    Gram-positive sticks (including Clostridium spp., Eubacterium spp. and Lactobacillus spp.).

    Pharmacokinetics:

    The maximum concentrations of sulbactam and cefoperazone after intravenous administration (w / w) 2 g of cefoperazone + sulbactam (1 g of sulbactam, 1 g of cefoperazone) for 5 minutes averaged 130 and 237 μg / ml, respectively. This reflects a higher volume of sulbactam distribution compared to that of cefoperazone.

    Both sulbactam and cefoperazone well distributed in a variety of tissues and fluids, including bile, gall bladder, skin, appendix, fallopian tubes, ovaries, uterus, etc. Sulbactam and cefoperazone penetrate through the placental barrier. When repeated application of significant changes in the pharmacokinetics of both components of the drug is not noted. With the introduction of the drug every 8-12 hours cumulation was not observed. Approximately 84% of the dose of sulbactam and 25% of the dose of cefoperazone administered as a combination - cefoperazone + sulbactam, is excreted by the kidneys. The rest of cefoperazone is excreted with bile. Cefoperazone Do not displace bilirubin from the connection with plasma proteins.The half-life (T1 / 2) of sulbactam averages about 1 hour, and cefoperazone - 1.7 hours. Serum concentration is proportional to the administered dose.

    When a violation of liver function

    Cefoperazone is actively excreted with bile. T1 / 2 cefoperazone usually lengthens, and the excretion of the drug by the kidneys increases in patients with liver disease and / or biliary tract obstruction. Even with a severe violation of liver function in the bile, a therapeutic

    the concentration of cefoperazone, and the half-life increases only 2-4 times. In case of impaired renal function

    In patients with varying degrees of renal impairment, cefoperazone + sulbactam, a high correlation was found between the total clearance of sulbactam from the body and the estimated clearance of creatinine. In patients with terminal renal insufficiency, a significant elongation of T1 / 2 sulbactam (up to 9.7 h) was revealed. Hemodialysis caused significant changes in the half-life, total clearance and volume of distribution of sulbactam.

    Application in the elderly

    The pharmacokinetics of cefoperazone + sulbactam has been studied in elderly people with renal insufficiency and impaired liver function.Compared with healthy volunteers, an increase in T1 / 2 duration, a decrease in clearance and an increase Vd both sulbactam and cefoperazone. The pharmacokinetics of sulbactam correlated with the degree of impaired renal function, and the pharmacokinetics of cefoperazone - with a degree of impaired hepatic function.

    Use in children

    In studies in children, no significant changes in the pharmacokinetics of the components of cefoperazone + sulbactam were found in comparison with those in adults. T1 / 2 sulbactam in children ranged from 0.9 to 1.4 hours, cefoperazone from 1.4 to 1.9 hours.

    Indications:
    Infectious-inflammatory diseases caused by sensitive microorganisms:

    - infections of the upper and lower respiratory tract;

    - urinary tract infections;

    - peritonitis, cholecystitis, cholangitis;

    - sepsis, meningitis;

    - infections of the skin and soft tissues;

    - infection of bones and joints;

    - inflammatory diseases of the pelvic organs, including endometritis, gonorrhea.
    Contraindications:Hypersensitivity to sulbactam, cefoperazone, penicillins and other beta-lactam antibiotics.
    Carefully:Severe violations of kidney and liver function, colitis (including in history), children's age of up to 3 months.
    Pregnancy and lactation:In pregnancy, the drug is used only if the expected benefit to the mother exceeds the potential risk to the fetus. If it is necessary to prescribe the drug during lactation, breastfeeding should be stopped.
    Dosing and Administration:

    Intravenous (struino and drip) and intramuscularly.

    Application in adults

    In adults cefoperazone + sulbactam it is recommended to use in the following daily doses:

    Ratio

    cefoperazone and sulbactam dose (g)

    sulbactam dose (g)

    cefoperazone dose (g)

    1:1

    2,0-4,0

    1,0-2,0

    1,0-2,0


    The daily dose should be divided into equal parts and administered every 12 hours. With severe and resistant to standard doses of infections, the daily dose of cefoperazone + sulbactam can be increased to 8 g at a ratio of the main components of 1: 1 (ie 4 g of cefoperazone). If you need more than 8 g (with a 1: 1 ratio of the main components), an increase in the dose is achieved by the additional administration of cefoperazone. The dose should be divided into equal parts and administered every 12 hours. The recommended maximum daily dose of sulbactam is 4 g.

    Application for renal dysfunction


    In patients with creatinine clearance of 15-30 ml / min, the maximum dose of sulbactam is 1 g every 12 hours (maximum daily dose of sulbactam 2 g), and in patients with creatinine clearance less than 15 ml / min the maximum dose of sulbactam is 500 mg every 12 hours the maximum daily dose of sulbactam 1 g). In severe infections, additional administration of cefoperazone may be required.

    The pharmacokinetics of sulbactam significantly changes during hemodialysis. The half-life of cefoperazone from the blood plasma is somewhat reduced during hemodialysis. Therefore, the administration of the drug should be planned after dialysis.

    Application for violations of liver function

    If regular monitoring of serum concentration of cefoperazone is not performed, the maximum daily dose should not exceed 2 g (see section "Special instructions"). Use in children

    Children cefoperazone + sulbactam it is recommended to use in the following daily doses:


    The dose ratio (mg / kg / day)

    cefoperazone + sulbactam dose (mg / kg / day)

    sulbactam

    cefoperazone

    1:1

    40-80

    20-40

    20-40

    The dose should be divided into equal parts and administered every 6-12 hours.

    With severe and resistant to standard doses of infections, the daily dosecan be increased to 160 mg / kg / day at a ratio of the main components of 1: 1. The daily dose is divided into 2-4 equal parts. If you need more than 80 mg / kg / day, calculated from the activity of cefoperazone, an increase in dose is achieved through the additional administration of cefoperazone.

    Neonatal application

    In newborns be administered every 12 hours. The maximum daily dose of sulbactam in children should not exceed 80 mg / kg / day during the first week of life of the drug.

    Method of preparing solutions for parenteral use

    Breeding:


    Total dose (g)

    Equivalent doses cefoperazone + sulbactam

    Volume of solvent, ml

    Maximum final concentration, mg / ml

    1,0

    0,5 + 0,5

    3,4

    125+125

    2,0

    1,0+1,0

    6.7

    125+125




    Intramuscular administration:

    Sterile water for injection is used for dissolution (see table). If the drug is administered at a concentration in excess of 250 mg / ml, it is recommended to prepare the solution using lidocaine. Dilution is carried out in 2 stages - in a vial containing 1 g of the drug, add 1.3 ml of sterile water for injections, in a vial containing 2 g - 2.6 ml, shake until completely dissolved, and then add to a vial containing 1 g 0.4 ml, into a vial containing 2 grams of 0.8 ml of a 2% solution of lidocaine hydrochloride.The final solution will contain in 1 ml of a 0.5% solution of lidocaine hydrochloride about 250 mg of cefoperazone and about 250 mg of sulbactam.

    Intravenous administration:

    For IV administration, the contents of the vial are dissolved in an adequate volume (see table) 5% dextrose solution, 0.9% sodium chloride solution, 5% dextrose solution in 0.225% sodium chloride solution, 5% dextrose solution in 0.9% sodium chloride solution or sterile water for injection and injected for 3 minutes.

    For IV infusion introduction dissolve, as mentioned above, then dilute to 20-100 ml with the same solvent and injected for 15-60 minutes.

    Preparation of the solution using Ringer's lactate. Since Ringer's lactate is not suitable for initial dilution, the solution is prepared in two steps: first use sterile water for injection (see table), and then dilute the resulting solution Ringer's lactate solution to a concentration of 5 mg / ml of sulbactam. Infusion is carried out for 15-60 minutes.

    Side effects:

    From the cardiovascular system: lowering of blood pressure.

    From the digestive system: diarrhea, nausea, vomiting, pseudomembranous

    colitis.

    Allergic reactions: maculopapular rash, hives, itching, Stevens-Johnson syndrome, anaphylactic shock.

    On the part of the hematopoiesis system: bleeding (vitamin K deficiency), a decrease in the number of neutrophils. With long-term treatment, reversible neutropenia, a decrease in hemoglobin and hematocrit, transient eosinophilia, thrombocytopenia, leukopenia, hypoprothrombinemia develops.

    Local reactions: sometimes, after a / m injection, there is transient pain and burning at the injection site. With iv administration of the drug, phlebitis may develop at the site of administration. Llaboratory indicators: hyperkreatininemia, transient increase in "liver" transaminases, alkaline phosphatase and bilirubin in blood serum, hematuria, false-positive Coombs test. When using a solution of Benedict or Felling, a false positive reaction to glucose in the urine can be observed.

    Other: headache, fever, chills, vasculitis.

    Overdose:
    Symptoms: neurological disorders, including convulsions.

    Treatment: symptomatic, hemodialysis is effective, especially in patients with impaired renal function.
    Interaction:
    Solutions cefoperazona + sulbactam and aminoglycosides should not be directly mixed, given the pharmaceutical incompatibility between them. If combined therapy is used, the two drugs are administered by successive infusions using separate secondary catheters, and the primary catheter is washed between doses of the drugs. Intervals between administration during the day should be as large as possible.
    When ethanol is used during treatment with cefoperazone and for up to 5 days after its administration, development of disulfiram-like effects, characterized by "hot flashes", sweating, headache and tachycardia, is possible.
    Patients who need artificial feeding (inside or parenteral) should avoid using solutions containing ethanol.
    Special instructions:
    The risk of hypersensitivity reactions, including those leading to death, is higher in patients who have a history of hypersensitivity reactions to many allergens. In case of an allergic reaction, it is necessary to cancel the drug and prescribe adequate therapy.
    Serious anaphylactic reactions require urgent epinephrine.Intravenously injected glucocorticosteroids and provide airway patency, including intubation.
    Dose changes may be required in cases of severe obstruction of the biliary tract, severe liver disease, and renal dysfunction associated with any of these conditions.
    In patients with impaired liver function and concomitant renal dysfunction, monitoring the serum concentration of cefoperazone and correcting its dose should be necessary. If regular monitoring of serum concentration of cefoperazone in such cases is not carried out, then its daily dose should not exceed 2 g.
    When using a solution of Benedict or Felling, a false positive reaction to glucose in the urine can be observed.
    With the simultaneous use of aminoglycosides, kidney function should be monitored.
    In the treatment of cefoperazonom in rare cases, vitamin K deficiency developed. Patients receiving malnutrition, suffering from malabsorption (for example, in cystic fibrosis) and those who are long-term on intravenous artificial feeding may be classified as a risk group.In such cases, as well as in patients receiving anticoagulants, it is necessary to monitor prothrombin time and, in the presence of indications, prescribe vitamin K.
    With prolonged treatment, excessive growth of insensitive microorganisms can be observed. With prolonged therapy, it is recommended to periodically monitor the performance of internal organs, including the kidneys, liver and hematopoiesis system.
    Form release / dosage:
    Powder for the preparation of solution for intravenous and intramuscular injection 0.5 g +0.5 g, 1.0 g + 1.0 g.
    Packaging:
    By 1.0 g or 2.0 g (0.5 g + 0.5 g, 1.0 g + 1.0 g) in glass bottles with a capacity of 20 ml of colorless glass, sealed with rubber stoppers, coated with aluminum caps with a safety plastic cover. One bottle together with the instruction for use is placed in a cardboard box.
    For hospitals: 50 bottles together with instructions for use are placed in a cardboard box.
    Storage conditions:List B. Store in a dry, the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:3 years. Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LSR-003639/10
    Date of registration:30.04.2010
    The owner of the registration certificate:Karnataka Antibiotics & Pharmaceuticals LimitedKarnataka Antibiotics & Pharmaceuticals Limited India
    Manufacturer: & nbsp
    Information update date: & nbsp28.10.2015
    Illustrated instructions
      Instructions
      Up